Gene therapy of type 2 diabetes mellitus: state of art
- 作者: Stafeev Y.1,2, Menshikov M1, Parfyonova Y.1,2
-
隶属关系:
- National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation
- M.V. Lomonosov Moscow State University
- 期: 卷 91, 编号 2 (2019)
- 页面: 149-152
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32975
- DOI: https://doi.org/10.26442/00403660.2019.02.000042
- ID: 32975
如何引用文章
全文:
详细
作者简介
Yu Stafeev
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation; M.V. Lomonosov Moscow State University
Email: yuristafeev@gmail.com
м.н.с. лаб. ангиогенеза НИИЭК ФГБУ НМИЦ кардиологии, аспирант кафедры биохимии и молекулярной медицины факультета фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова» Moscow, Russia
M Menshikov
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federationд.б.н., в.н.с. лаб. ангиогенеза НИИЭК ФГБУ «НМИЦ кардиологии» Moscow, Russia
Ye Parfyonova
National Medical Research Centre for Cardiology of the Ministry of Health of the Russian Federation; M.V. Lomonosov Moscow State Universityд.м.н., зав. лаб. ангиогенеза и директор НИИЭК «ФГБУ НМИЦ кардиологии», зав. лаб. постгеномных технологий в медицине факультета фундаментальной медицины ФГБОУ ВО «МГУ им. М.В. Ломоносова» Moscow, Russia
参考
- Naldini L. Medicine. A comeback for gene therapy. Science. 2009;326:805-6. doi: 10.1126/science.1181937
- Herzog R.W, Cao O, Srivastava A. Two decades of clinical gene therapy - success is finally mounting. Discov Med. 2010;9:105-11.
- Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-3. doi: 10.1126/science.342.6165.1432
- Williams P.D, Kingston P.A. Plasmid - mediated gene therapy for cardiovascular disease. Cardiovasc Res. 2011;91:565-76. doi: 10.1093/cvr/cvr197
- Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanohara A, Friedmann T, Risau W, Martin J.F, Soma M, Ylä-Herttuala S. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid - liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther. 1997;8:1645-50. doi: 10.1089/hum.1997.8.14-1645
- Edwards C.M. GLP-1: target for a new class of antidiabetic agents? J R Soc Med. 2004;97:270-4.
- Herzberg-Schäfer S, Heni M, Stefan N, Häring H.U, Fritsche A. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes Obes Metab. 2012;14:85-90. doi: 10.1111/j.1463-1326.2012.01648.x
- Domínguez Avila J.A, Rodrigo García J, González Aguilar G.A, de la Rosa L.A. The antidiabetic mechanisms of polyphenols related to increased glucagon - like peptide-1 (GLP1) and insulin signaling. Molecules. 2017;22:E933. doi: 10.3390/molecules22060903
- Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat - derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-63. doi: 10.2337/diabetes.52.7.1655
- Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92. doi: 10.1172/JCI29126
- Fisman E.Z, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103. doi: 10.1186/1475-2840-13-103
- Choi S, Oh S, Lee M, Kim S.W. Glucagon - like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther. 2005;12:885-91. doi: 10.1016/j.ymthe.2005.03.039
- Parsons G.B, Souza D.W, Wu H, Yu D, Wadsworth S.G, Gregory R.J, Armentano D. Ectopic expression of glucagon - like peptide 1 for gene therapy of type II diabetes. Gene Ther. 2007;14:38-48. doi: 10.1038/sj.gt.3302842
- Jean M, Alameh M, Buschmann M.D, Merzouki A. Effective and safe gene - based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther. 2011;18:807-16. doi: 10.1038/gt.2011.25
- Vilsboll T. Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc.). 2009;45:101-13. doi: 10.1358/dot.2009.45.2.1336104
- Verges B, Bonnard C, Renard E. Beyond glucose lowering: glucagon - like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37:477-88. doi: 10.1016/j.diabet.2011.07.001
- Garber A.J. Liraglutide in oral antidiabetic drug combination therapy. Diabetes Obes Metab. 2012;14:13-9. doi: 10.1111/j.1463-1326.2012.01574.x
- Kim P.H, Lee V, Nam K, Kim S.W. Enhanced incretin effects of exendin-4 expressing chimeric plasmid based on two - step transcription amplification system with dendritic bioreducible polymer for the treatment of type 2 diabetes. J Gene Ther. 2013;1:7-15. doi: 10.13188/2381-3326.1000002
- Park J.H, Lee M, Kim S.W. Non - viral adiponectin gene therapy into obese type 2 diabetic mice ameliorates insulin resistance. J Control Release. 2006;114:118-25. doi: 10.1016/j.jconrel.2006.05.008
- Nan M.H, Park J.S, Myung C.S. Construction of adiponectin - encoding plasmid DNA and gene therapy of non - obese type 2 diabetes mellitus. J Drug Target. 2010;18:67-77. doi: 10.3109/10611860903225719
- Kandasamy A.D, Sung M.M, Boisvenue J.J, Barr A.J, Dyck J.R. Adiponectin gene therapy ameliorates high - fat, high - sucrose diet - induced metabolic perturbations in mice. Nutr Diabetes. 2012;2:e45. doi: 10.1038/nutd.2012.18
- Halenova T, Savchuk O, Ostapchenko L, Chursov A, Fridlyand N, Komissarov A, Venanzi F, Kolesnikov I, Sufianov A, Sherman M, Gabai L, Shneider A. P62 plasmid can alleviate diet - induced obesity and metabolic dysfunctions. Oncotarget. 2017;8:56030-40. doi: 10.18632/oncotarget.19840
- Jimenez V, Muñoz S, Casana E, Mallol C, Elias I, Jambrina C, Ribera A, Ferre T, Franckhauser S, Bosch F. In vivo adeno - associated viral vector - mediated genetic engineering of white and brown adipose tissue in adult mice. Diabetes. 2013;62:4012-22. doi: 10.2337/db13-0311
- O'Neill S.M, Hinkle C, Chen S.J, Sandhu A, Hovhannisyan R, Stephan S, Lagor W.R, Ahima R.S, Johnston J.C, Reilly M.P. Targeting adipose tissue via systemic gene therapy. Gene Ther. 2014;21:653-61. doi: 10.1038/gt.2014.38
- Gomez-Banoy N, Lo J.C. Genetic manipulation with viral vectors to assess metabolism and adipose tissue function. Meth Mol Biol. 2017;1566:109-24. doi: 10.1007/978-1-4939-6820-6_11
- Riedel M.J, Gaddy D.F, Asadi A, Robbins P.D, Kieffer T.J. DsAAV8-mediated expression of glucagon - like peptide-1 in pancreatic beta - cells ameliorates streptozotocin - induced diabetes. Gene Ther. 2010;17:171-80. doi: 10.1038/gt.2009.143
- Lee Y, Kwon M.K, Kang E.S, Park Y.M, Choi S.H, Ahn C.W, Kim K.S, Park C.W, Cha B.S, Kim S.W, Sung J.K, Lee E.J, Lee H.C. Adenoviral vector - mediated glucagon - like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. J Gene Med. 2008;10:260-8. doi: 10.1002/jgm.1153
- Tasyurek H.M, Altunbas H.A, Balci M.K, Griffith T.S, Sanlioglu S. Therapeutic potential of lentivirus - mediated glucagon - like peptide-1 gene therapy for diabetes. Hum Gene Ther. 2018;29:802-15. doi: 10.1089/hum.2017.180
- Kojima S, Asakawa A, Amitani H, Sakoguchi T, Ueno N, Inui A, Kalra S.P. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia, and promote survival in insulin - deficient diabetic mice. Peptides. 2009;30:962-6. doi: 10.1016/j.peptides.2009.01.007
- Wang Y, Asakawa A, Inui A, Kosai K. Leptin gene therapy in the fight against diabetes. Expert Opin Biol Ther. 2010;10:1405-14. doi: 10.1517/14712598.2010.512286
- Lee M.W, Odegaard J.I, Mukundan L, Qiu Y, Molofsky A.B, Nussbaum J.C, Yun K, Locksley R.M, Chawla A. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell. 2015;160:74-87. doi: 10.1016/j.cell.2014.12.011
- Stafeev I.S, Michurina S.S, Podkuychenko N.V, Vorotnikov A.V, Menshikov M.Y, Parfyonova Ye.V. Interleukin-4 restores insulin sensitivity in lipid - induced insulin resistant adipocytes. Biochemistry (Mosc). 2018;83:498-506. doi: 10.1134/S0006297918050036
- Michurina S, Stafeev I, Beloglazova I, Molokotina Y, Shevchenko E, Vorotnikov A, Menshikov M, Parfyonova Ye. Lentiviral transfer of interleukin 4 gene to 3T3-L1 adipocytes prevents development of lipid - induced insulin resistance. Eur Heart J. 2018;39:492. doi: 10.1093/eurheartj/ehy565.P2524